Effect of valsartan on endothelial function, carotid intima-media thickness, left ventricular mass, arterial compliance, inflammation and coagulation abnormalities in the metabolic syndrome.

Trial Profile

Effect of valsartan on endothelial function, carotid intima-media thickness, left ventricular mass, arterial compliance, inflammation and coagulation abnormalities in the metabolic syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2017

At a glance

  • Drugs Valsartan (Primary)
  • Indications Metabolic syndrome
  • Focus Pharmacodynamics
  • Most Recent Events

    • 04 Jan 2012 Actual end date (Dec 2011) added as reported by ISRCTN: Current Controlled Trials.
    • 04 Jan 2012 Actual initiation date (Jan 2008) added as reported by ISRCTN: Current Controlled Trials
    • 04 Jan 2012 Planned number of patients changed from 80 to 120 as reported by ISRCTN: Current Controlled Trials
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top